KeraStat Skin Therapy in Treating Radiation Dermatitis in Patients With Newly Diagnosed Stage 0-IIIA Breast Cancer

Inclusion Criteria:

Newly diagnosed with breast carcinoma, stage 0-IIIA (including ductal carcinoma in situ [DCIS])
Status post-lumpectomy, -quadrantectomy, or -mastectomy
Plan to receive adjuvant radiation to the whole breast or chest wall +/- regional lymph nodes
Total dose >= 40Gy
Dose per fraction >= 1.8 use of 2-dimensional (2D), 3-dimensional (3D) conformal, or intensity-modulated radiation therapy (IMRT) treatment techniques allowed; skin sparing IMRT patients excluded; a daily fraction of 2.7 Gy to the whole breast is suggested for hypofractionated regimens
Concurrent and sequential boost techniques are allowed for both standard and hypofractionated regimens
Adjuvant hormonal therapy will be allowed prior to, during and/or after RT at the discretion of a medical oncologist
Targeted therapies such as Herceptin will be allowed prior to, during, and/or after RT at the discretion of the medical oncologist
Patients who are able and willing to sign protocol consent form

Exclusion Criteria:

Prior radiation to the involved breast or chest wall
Concurrent chemotherapy; (patients may receive chemotherapy prior to radiation or following radiation at the treating physician's discretion)
Patients who underwent breast reconstruction following mastectomy (placement of tissue expanders and implants are not allowed)
Patients undergoing partial breast irradiation
Patients who have undergone MammoSite® or any other form of brachytherapy
Patients may not be concurrently enrolled in a protocol that involves treatment of the skin ie: applying lotions /moisturizers; protocols that do not involve treatment of the skin are allowed
Patients who are pregnant or breastfeeding